| Ms Melodee Angela Corne, CNM | |
|
100 S. Boylan Ave, Raleigh, NC 27603-2512 | |
| (919) 833-7526 | |
| (919) 832-9061 |
| Full Name | Ms Melodee Angela Corne |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 100 S. Boylan Ave, Raleigh, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659743052 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 885 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Melodee Angela Corne, CNM 100 S. Boylan Ave, Raleigh, NC 27603 Ph: (919) 833-7526 | Ms Melodee Angela Corne, CNM 100 S. Boylan Ave, Raleigh, NC 27603-2512 Ph: (919) 833-7526 |
News Archive
Argos Therapeutics today announced two oral presentations detailing data on its soluble CD83 (sCD83) protein program at the 2010 American Transplant Congress, held May 1-5 in San Diego. The data, which were produced by Argos in collaboration with scientists from the University of Western Ontario, demonstrate that sCD83 is capable of inducing immune system tolerance to transplant grafts and suppressing an anti-donor antibody response, via a multi-faceted mechanism-of-action that impacts B and T cells, as well as dendritic cells.
Recently, researchers discovered that quercetin, a key ingredient in the natural antiviral supplement Gene-Eden, may be beneficial against the flu virus.
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and glucosylceramides are metabolized. Mayo Clinic researchers have found that Parkinson's patients who do not carry the genetic mutation also have higher levels of these lipids in the blood. Further, those who had Parkinson's and high blood levels were also more likely to have cognitive impairment and dementia.
› Verified 9 days ago
Chelsey Hilscher, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 10 Sunnybrook Road, Clinic G, Wchs, Raleigh, NC 27610 Phone: 919-250-4701 | |
Mrs. Tianna Kathryn Powell Greene, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 4414 Lake Boone Trl, Raleigh, NC 27607 Phone: 919-351-8253 | |
Jessica Lynn Albrecht, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 4414 Lake Boone Trl Ste 402, Raleigh, NC 27607 Phone: 919-567-6133 | |
Lisa Stevens, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 10 Sunnybrook Rd, Raleigh, NC 27610 Phone: 919-212-7000 | |
Mrs. Julie Ann Stembridge, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 3024 New Bern Ave, Raleigh, NC 27610 Phone: 919-350-7331 | |
Kathryn Anne Wood Calvillo, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 4414 Lake Boone Trl Ste 300, Raleigh, NC 27607 Phone: 919-781-5510 | |
Cassandra Lagod, Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 1500 Garner Rd, Raleigh, NC 27610 Phone: 919-556-1008 |